2Department of Cardiology, Kahramanmaras Necip Fazıl City Hospital, Kahramanmaras, Turkey
3Department of Cardiology, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey
4Department of Cardiology, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey
5Department of Cardiology, Kafkas University Medical Faculty, Kars, Turkey
6Department of Cardiology, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey
7Department of Cardiology, Hitit University Corum Erol Olcok Training and Research Hospital, Corum, Turkey
8Department of Cardiology, Bulent Ecevit Universiy Medical Faculty, Zonguldak, Turkey
9Department of Cardiology, Mehmet Akif İnan Training and Research Hospital, Sanlıurfa, Turkey
10Department of Cardiology, Adıyaman University, Training and Research Hospital, Adıyaman, Turkey
11Department of Cardiology, Kirikkale Yuksek İhtisas Hospital, Kirikkale, Turkey
12Department of Cardiology, Eskisehir Osmangazi University, Faculty of Medicine, Eskisehir, Turkey
13Department of Cardiology, Kayseri Training and Research Hospital, Kayseri, Turkey
Abstract
Objective: Although almost half of chronic heart failure (HF) patients have mid-range (HFmrEF) and preserved left-ventricular ejection fraction (HFpEF), no studies have been carried out with these patients in our country. This study aims to determine the demographic characteristics and current status of the clinical background of HFmrEF and HFpEF patients in a multicenter trial.
Methods: A comPrehensive, ObservationaL registry of heart faiLure with mid-range and preserved ejectiON fraction (APOLLON) trial will be an observational, multicenter, and noninterventional study conducted in Turkey. The study population will include 1065 patients from 12 sites in Turkey. All data will be collected at one point in time and the current clinical practice will be evaluated (ClinicalTrials.gov number NCT03026114).
Results: We will enroll all consecutive patients admitted to the cardiology clinics who were at least 18 years of age and had New York Heart Association class II, III, or IV HF, elevated brain natriuretic peptide levels within the last 30 days, and an left ventricular ejection fraction (LVEF) of at least 40%. Patients fulfilling the exclusion criteria will not be included in the study. Patients will be stratified into two categories according to LVEF: mid-range EF (HFmrEF, LVEF 40%-49%) and preserved EF (HFpEF, LVEF ≥50%). Regional quota sampling will be performed to ensure that the sample was representative of the Turkish population. Demographic, lifestyle, medical, and therapeutic data will be collected by this specific survey.
Conclusion: The APOLLON trial will be the largest and most comprehensive study in Turkey evaluating HF patients with a LVEF ≥40% and will also be the first study to specifically analyze the recently designated HFmrEF category.